Category

Multiple Sclerosis

Oral administration of cannabis with lipids leads to high levels of cannabinoids in the intestinal lymphatic system and prominent immunomodulation.

By | Immune System Diseases , Multiple Sclerosis

Authors: Atheer Zgair, Jong Bong Lee, Jonathan C. M. Wong, Dhiaa A. Taha, Jehan Aram, et al
Scientific Reports, 6 November 2017

Cannabidiol (CBD) and ∆9-tetrahydrocannabinol (THC) have well documented immunomodulatory effects in vitro, but not following oral administration in humans. Here we show that oral co-administration of cannabinoids with lipids can substantially increase their intestinal lympha…

Read More

Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis.

By | Immune System Diseases , Multiple Sclerosis

Authors: R. B. C. Kavia, D. De Ridder, C. S. Constantinescu, C. G. Stott, C. J. Fowler
Multiple Sclerosis Journal, November 2016

BACKGROUND: Bladder dysfunction is a common feature of multiple sclerosis (MS). OBJECTIVE: In this study we aimed to assess the efficacy, tolerability and safety of Sativex(®) (nabiximols) as an add-on therapy in alleviating bladder symptoms in patients with MS. METHODS: We un…

Read More

Role of Endocannabinoid Activation of Peripheral CB1 Receptors in the Regulation of Autoimmune Disease.

By | Arthritis, Immune System Diseases , Joint Diseases (Arthrosis), Multiple Sclerosis

Authors: Jessica Margaret Sido, Prakash S. Nagarkatti, Mitzi Nagarkatti
International Reviews of Immunology, 2015

The impact of the endogenous cannabinoids (AEA, 2-AG, PEA, and virodamine) on the immune cell expressed cannabinoid receptors (CB1, CB2, TRPV-1, and GPR55) and consequent regulation of immune function is an exciting area of research with potential implications in the preventio…

Read More

An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis.

By | Immune System Diseases , Multiple Sclerosis

Authors: C. M. Brady, R. DasGupta, C. Dalton, O. J. Wiseman, K. J. Berkley, C. J. Fowler
Multiple Sclerosis Journal, 1 August 2004

The majority of patients with multiple sclerosis (MS) develop troublesome lower urinary tract symptoms (LUTS). Anecdotal reports suggest that cannabis may alleviate LUTS, and cannabinoid receptors in the bladder and nervous system are potential pharmacological targets. In an o…

Read More